Just In
- 2 hrs ago Daily Horoscope, 19 April 2024: Gemini Will Have A Controversial Day In Terms Of Love
- 6 hrs ago Kamada Ekadashi 2024 Wishes: Greetings, Messages, Texts, Images, Twitter Status And Instagram Captions
- 6 hrs ago Deepika Padukone's 6 Refreshing Skincare Tips to Beat the Summer Heat
- 11 hrs ago 7 Questions You Should Ask Your Partner Before Getting Into An Arranged Marriage
Don't Miss
- Finance Stock Market Live Updates: Nifty Forecast To Lose Each Week; Infosys's ADR Dips 2.6% Over Night
- Movies Bade Miyan Chote Miyan Box Office Day 9 Prediction: Akshay’s Film To Cross 51Cr Ahead Of 2nd Weekend
- Sports LSG vs CSK IPL 2024: Four Batters Who Can Score Most Runs in Match 34
- News 12 Jurors Picked For Donald Trump’s Hush Money Trial, Alternate Selection Continues
- Automobiles Aprilia RS 457 Accessories: A Detailed Look At The Prices
- Education Karnataka SSLC Result 2024 Soon, Know How to Check Through Website, SMS and Digilocker
- Technology Nothing Ear, Ear a With ANC, Up to 42.5 Hours of Battery Launched; Check Price and Availability
- Travel Telangana's Waterfall: A Serene Escape Into Nature's Marvels
Biological E Hopes To Roll Out COVID-19 Vaccine Corbevax By November-End
Biological E. Limited (BE) is expecting its COVID-19 vaccine Corbevax to be rolled out by the end of November even as the city-based firm is getting ready with 100 million doses for the launch, Mahima Datla, Managing Director, BE said on Monday.
Speaking to reporters on the sidelines of signing a financing agreement with US International Development Finance NSE 6.68 % Corporation (DFC), she said currently the manufactured doses are being sent to Central Drugs Laboratory (CDL), Kasauli in Himachal Pradesh for regulatory testing.
"Corbevax is in phase 3 trials. We are likely to complete all the studies by end of November which is when we are expecting licence (from the drug regulator). The licence for children should follow one month later. The study in children is underway as well," she said.
Deficiency Of These Vitamins And Minerals Can Cause Insomnia
Biological E's anti-coronavirus shot, Corbevax, is a RBD protein sub-unit vaccine and is currently undergoing phase 2/3 clinical trials on adults.
The Phase 3 trials are going to be a study in comparison with the already licensed vaccines, though the study in children is not a comparative study, she further said.
"We are submitting doses to Kasauli for release. So it is my hope that at the day of launch, it has always been our vision to have close to ten crore doses on the day. By the end of November this may happen as soon as we get the license," she said.
On the COVID-19 vaccine manufacturing capacities, she said currently BE has the capacity to make one billion doses of Corbevax per annum, and 600 million doses of Johnson & Johnson's jab.
Biological E Ltd had earlier said it entered into an agreement with Janssen Pharmaceutica NV, part of pharma major Johnson & Johnson, for creation and enhancement of production capabilities to manufacture the latter's COVID-19 vaccine.
Meanwhile, DFC's Chief Operating Officer David Marchick and Mahima Datla today unveiled the expansion of Biological E.'s vaccine manufacturing facility here and finalised a U.S. government financing arrangement formalising USD 50 million to expand the company's capacity to produce COVID-19 vaccines.
"DFC's partnership with Biological E will support capacity for production of more than one billion vaccine doses by the end of 2022 for India and for developing countries around the world," Marchick said in a press release.
"We are pleased with the financial support from the U.S. government, especially DFC, which was announced at the Quad Summit in March 2021. This investment will not only help us augment our capacity to produce more COVID-19 vaccines, but also help the global community that has been relentlessly fighting against the spread of the COVID-19 pandemic," Mahima Datla said.
- disorders cureIndia May See A Covid Surge In January, Next 40 Days Crucial; Here Is How To Protect Yourself From COVID-19
- disorders cureCOVID Can Trigger Parkinson's Disease: Study
- disorders cureCommon COVID Symptoms In Fully Vaccinated Individuals: What You Should Know
- wellnessMild COVID Linked To Life-Threatening Blood Clots, Increased Risk Of Cardiovascular Disease; Study
- wellnessCOVID-19 Variants In India: New COVID Variant May Pose Threat To Elderly People
- basicsCovid-19 Linked To Early Onset Of Periods: What You Need To Know
- wellnessCOVID XBB Variants Of Omicron In India: What You Should Know
- disorders cureNew Omicron Subvariant BQ.1 Detected In Maharashtra: What You Should Know
- disorders cureOmicron BF.7 In India, Risk Of Fresh Wave During Diwali: What You Should Know
- womenPriyanka Chopra Speaks On Climate Change, COVID, Poverty At The UN Sustainable Development Goals 2022 Moment
- wellnessCoronavirus Residues Might Be Causing Long COVID: New Study
- art cultureRenowned Spanish Author Javier Marias Passes Away Due To Lung Infection Post COVID-19